Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
762.300.04%
QQQ
716.380.08%
BTC/USD
76435.110.2984%
DIA
518.090.05%
GLD
398.010.09%
TLT
81.720.07%

Design Therapeutics Inc (DSGN) Stock Price, Quote, News & History

DSGNNASDAQ
Trade with Public
Trade with Public
$12.81
0.302.44%
At close: Sep 17, 5:00 PM EST
$12.81
N/A
After Hours: 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Design Therapeutics (DSGN) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
$12.73
Close
$12.81
Volume / Avg.
601.08K / 714.17K
Day Range
$12.17 - $12.90
52 Wk Range
5.28 - 17.25
Market Cap
$800.07M
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
36
Short Interest
11.76%
Days to Cover
8.98

Recent Design Therapeutics, Inc. News

Marvell Technology, PayPal, Rubrik And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

U.S. stock futures mostly lower, Nasdaq 100 down 0.3%. Marvell Technology shares fall 7.6% after beating estimates, other stocks also drop in pre-market.
Avi Kapoor

TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday

TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other big gainers include IMVT, SLS, TE, VUZI, ROIV, POET, ARM, AMC, ALAB, DSGN, and TLN.
Avi Kapoor

Design Therapeutics Stock Wobbles After Rare Genetic Disease Data

Design Therapeutics reported Phase 1/2 data for DT-216P2, showing biomarker and clinical improvements in Friedreich ataxia patients.
Vandana Singh

Crude Oil Gains Over 2%; US Homebuilder Sentiment Increases In May

Dow falls over 100 points, NASDAQ down 1.20% and S&P 500 down 0.64%. Energy shares surge, tech stocks drop. NAHB/Wells Fargo Housing Market Index up to 37.
Avi Kapoor

Nasdaq Down 200 Points; Brady Earnings Top Views

US stocks lower as Nasdaq falls 200 points, Dow down 0.04% and S&P 500 down 0.37%. Energy shares up 1.8%, tech stocks down 1.6%. Brady Corp reports strong earnings. Sunshine Biopharma, Virax Biolabs, Wellgistics up, AiRWA, Aditxt, Design Therapeutics down.
Avi Kapoor

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-55.08M
Investing Cash Flow (TTM)
2.39M
Financing Cash Flow (TTM)
45.89M
Free Cash Flow (TTM)
-55.14M
Capital Expenditure (TTM)
-55.00K
Net Change in Cash (TTM)
-6.80M

Analyst Trends and Forecast

1
May
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
4.3
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$577.85M
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
-
PB Ratio (TTM)
3.88
Earnings Yield % (TTM)
-9.44%
Earnings Yield % (FWD)
-13.35%
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$3.23

Company Debt

Total Debt
-
LT Debt
-
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
-
Total Cash
$12.91M
Debt to Equity
0.01
Issuance of Debt (TTM)
-
Repayment of Debt (TTM)
-

Key Statistics

Open
$12.73
Close
$12.81
Volume / Avg.
601.08K / 714.17K
Day Range
$12.17 - $12.90
52 Wk Range
5.28 - 17.25
Market Cap
$800.07M
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
36
Short Interest
11.76%
Days to Cover
8.98

About

Sector
Health Care
Industry
Biotechnology
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifyin...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy Design Therapeutics (DSGN) stock?

A

You can purchase shares of Design Therapeutics (NASDAQ:DSGN) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Design Therapeutics (DSGN) competitors?

Q

What is the forecast, or price target, for Design Therapeutics (DSGN) stock?

A

Design Therapeutics has a consensus price target of $14.14.

Q

What is the current price for Design Therapeutics (DSGN)?

A

The stock price for Design Therapeutics (NASDAQ: DSGN) is $12.81 last updated September 17, 2026 at 4:00 PM EDT.

Q

Does Design Therapeutics (DSGN) pay a dividend?

A

There are no upcoming dividends for Design Therapeutics.

Q

When is Design Therapeutics (NASDAQ:DSGN) reporting earnings?

A

Design Therapeutics does not have any upcoming earnings scheduled.

Q

Is Design Therapeutics (DSGN) going to split?

A

There is no upcoming split for Design Therapeutics.

Q

What sector and industry does Design Therapeutics (DSGN) operate in?

A

Design Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved